For instance, to improve the efficacy of autologous cell therapy, the dystrophin-deficient MuSCs collected from DMD patient and corrected by CRISPR prime editing (Happi Mbakam et al., 2022) could be treated with MS023 to maintain their stemness and enhance their cell engraftment capacity. This evidence concerns the gene DMD and Duchenne muscular dystrophy.